Bellevue Group Ag Biogen Inc. Transaction History

Bellevue Group Ag

$5.98 Billion
Q2 2024

A detailed history of Bellevue Group Ag transactions in Biogen Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 5,902 shares of BIIB stock, worth $1.03 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

5,902

Previous 6,008 1.76%

Holding current value

$1.03 Million

Previous $1.3 Million 5.64%

% of portfolio

0.02%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$190.52 - $236.72 $20,195 - $25,092	-106 Reduced 1.76%	5,902 $1.37 Million
Q1 2024 May 15, 2024	SELL	$212.02 - $267.71 $525,173 - $663,117	-2,477 Reduced 29.19%	6,008 $1.3 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $1.97 Million - $2.37 Million	-8,829 Reduced 50.99%	8,485 $2.2 Million
Q3 2023 Nov 14, 2023	SELL	$253.3 - $285.89 $2.1 Million - $2.37 Million	-8,284 Reduced 32.36%	17,314 $4.45 Million
Q2 2023 Aug 14, 2023	BUY	$275.25 - $318.06 $246,073 - $284,345	894 Added 3.62%	25,598 $7.29 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $949,272 - $1.08 Million	-3,700 Reduced 13.03%	24,704 $6.87 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $83,557 - $101,524	-331 Reduced 1.15%	28,404 $7.87 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $1.34 Million - $1.85 Million	6,885 Added 31.51%	28,735 $7.67 Million
Q2 2022 Aug 11, 2022	SELL	$187.54 - $223.02 $93,770 - $111,510	-500 Reduced 2.24%	21,850 $4.46 Million
Q1 2022 May 13, 2022	SELL	$193.77 - $244.14 $97.4 Million - $123 Million	-502,650 Reduced 95.74%	22,350 $4.71 Million
Q4 2021 Feb 10, 2022	SELL	$223.92 - $287.77 $447,840 - $575,540	-2,000 Reduced 0.38%	525,000 $126 Million
Q3 2021 Nov 12, 2021	SELL	$282.99 - $369.05 $311,289 - $405,955	-1,100 Reduced 0.21%	527,000 $149 Million
Q2 2021 Aug 12, 2021	SELL	$259.0 - $414.71 $7.85 Million - $12.6 Million	-30,300 Reduced 5.43%	528,100 $183 Million
Q1 2021 May 12, 2021	SELL	$242.95 - $284.63 $1.36 Million - $1.59 Million	-5,600 Reduced 0.99%	558,400 $156 Million
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $131 Million - $198 Million	555,400 Added 6458.14%	564,000 $138 Million
Q3 2020 Nov 16, 2020	BUY	$264.77 - $305.71 $2.28 Million - $2.63 Million	8,600 New	8,600 $2.44 Million
Q2 2020 Aug 13, 2020	SELL	$258.66 - $342.55 $2.2 Million - $2.91 Million	-8,500 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$268.85 - $341.04 $2.15 Million - $2.73 Million	8,000 Added 1600.0%	8,500 $2.69 Million
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $7.01 Million - $9.68 Million	-31,850 Reduced 98.45%	500 $148,000
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $608,832 - $682,864	2,800 Added 9.48%	32,350 $7.53 Million
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $4.63 Million - $5.1 Million	21,100 Added 249.7%	29,550 $6.91 Million
Q1 2019 May 15, 2019	SELL	$216.71 - $338.96 $3.64 Million - $5.69 Million	-16,800 Reduced 66.53%	8,450 $2 Million
Q4 2018 Feb 12, 2019	SELL	$278.5 - $352.75 $3.9 Million - $4.94 Million	-13,995 Reduced 35.66%	25,250 $7.6 Million
Q3 2018 Nov 13, 2018	SELL	$293.51 - $383.83 $29,351 - $38,383	-100 Reduced 0.25%	39,245 $13.9 Million
Q2 2018 Aug 07, 2018	SELL	$257.52 - $306.91 $1.77 Million - $2.1 Million	-6,855 Reduced 14.84%	39,345 $11.4 Million
Q1 2018 May 09, 2018	SELL	$260.13 - $367.91 $1.59 Million - $2.24 Million	-6,100 Reduced 11.66%	46,200 $12.7 Million
Q4 2017 Feb 14, 2018	SELL	$307.64 - $344.58 $2.03 Million - $2.27 Million	-6,600 Reduced 11.21%	52,300 $16.7 Million
Q3 2017 Nov 13, 2017	SELL	$281.15 - $329.69 $730,989 - $857,194	-2,600 Reduced 4.23%	58,900 $18.4 Million
Q2 2017 Aug 14, 2017	BUY	N/A	61,500	61,500 $16.7 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Biogen Inc. Transaction History